$Ocugen(OCGN.US$
Ocugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s gene therapy candidate, OCU400.
The decision comes after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), reviewed the critical components of the company's Phase 3 liMeliGhT clinical trial for OCU400...
Ocugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s gene therapy candidate, OCU400.
The decision comes after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), reviewed the critical components of the company's Phase 3 liMeliGhT clinical trial for OCU400...
1